Sign In

Andrew Cleeland

Fogarty Innovation

Andrew Cleeland is a seasoned executive with over 30 years of experience in the medical device industry.23 He joined the Board of Directors at Francis Medical in January 2023.14 Cleeland is currently the CEO of Fogarty Innovation, a position he has held since 2017.35 He has an extensive background in healthcare innovation and medical technology development.1

Some key aspects of Andrew Cleeland's career include:

  1. Leadership roles:

    • CEO of Fogarty Innovation (2017-present)3
    • Chairman of the Board at Zenflow, Inc. and Medical Microinstruments SpA23
    • Former President and CEO of Twelve, Inc. (2012-2015)3
    • Former President and CEO of Ardian, Inc. (2006-2012)3
  2. Board positions:

    • Director at Saluda Medical Pty Ltd.2
    • Director at Medical Device Innovation Consortium2
    • Member of the Biomedical Advisory Council at Agency for Science, Technology & Research2
  3. Industry experience:

    • Vice President & General Manager of Transcatheter Mitral Valve Replacement at Medtronic (2015-2018)3
    • Vice President at Radiant Medical (1999-2006)3
    • Roles at Baxter Healthcare and Telectronics Pacing Systems3

Cleeland's education includes a Bachelor of Applied Science in Biophysics from Swinburne University of Technology.23 His expertise in medical technology innovation and successful development of healthcare solutions makes him a valuable addition to Francis Medical's board as they work on their water vapor ablation therapy for cancer treatment.14

Highlights

Aug 11 · linkedin

Great to see Jonathan Norris’ inaugural HSBC Venture Healthcare Report covering the first half of 2023. Always enjoy and appreciate his work!

#HSBCInnovationBanking #HSBCHealthcare

Apr 2 · linkedin

"You can measure a man’s character by the choices he makes under pressure.” — Winston Churchill  There were plenty of opportunities to gauge our own character and that of others in March, with challenges ranging from flooded roads and falling trees to the departure of two foundational members of our ecosystem. With regard to the latter, I hope many of you had the opportunity to attend Stanford Byers Center for Biodesign's latest Innovator’s Workbench event honoring Casey McGlynn, who recently retired from his position as a partner at Wilson Sonsini Goodrich & Rosati (WSGR). Although many people know Casey, few appreciate the magnitude of the role he played in building the medtech industry in Silicon Valley. He established WSGR’s medical devices practice in 1990 and has personally formed, represented, sold or taken public many of the most important medical device and diagnostic companies founded over the past thirty years. He has also given back in spades – regularly providing advice and connections to his influential network without any expectation of payback. His goal is always to help innovators bring important ideas to patients, and his actions consistently reflect his tremendous generosity of spirit. We are fortunate to have Casey as a member of Fogarty Innovation's board of directors and are hopeful that in retirement, he will have even more time to be actively involved with our organization. On that note, I’d like to recognize and acknowledge his wife Kathy, for her unqualified support of Casey, our industry, Fogarty Innovation, and me personally. Casey is lucky to have her and by association, we are too.  The second departure is, of course, Silicon Valley Bank (SVB), which for the past 40 years has supported the startup medtech ecosystem as a trusted partner to companies and the venture capital industry. Although all was clearly not well behind the scenes, I was stunned by the bank’s swift downfall. I was also, quite frankly, pissed off at the lack of character shown by those who accelerated the crisis by advocating the withdrawal of funds, then were the first to call for governmental relief. At the same time, however, I was heartened by the support, commitment and ingenuity of our innovation community. This was amply demonstrated as venture firms wrote new pages in their playbooks in an effort to make cash accessible when it appeared that hundreds of companies would be unable to make payroll. It was also visible in the stream of individuals reaching out personally to longtime SVB employees who have been our great friends and business partners for years. While this is a tough turn of events, we will get past it and find new ways to continue working with those who have earned our unqualified trust and respect. To read the rest of our April newsletter, including news on the first clinical use of FloPatch from FI grad Flosonics Medical at El Camino Health, click here: https://lnkd.in/g9dyWJDh

Related Questions

What are Andrew Cleeland's main responsibilities at Francis Medical?
How has Andrew Cleeland's career evolved in the medical device industry?
What is the significance of Andrew Cleeland's role at Fogarty Institute for Innovation?
How does Andrew Cleeland's experience at Medtronic influence his current positions?
What are the key projects Andrew Cleeland has been involved in at Zenflow, Inc?
Andrew Cleeland
Andrew Cleeland, photo 1
Andrew Cleeland, photo 2
Add to my network

Location

Palo Alto, California, United States